Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Researchers have found that GlaxoSmithKline’s ezogabine (Potiga), approved by the FDA in 2011 as an anti-seizure therapy, could have applications as a treatment for treatment-resistant depression

pharmafileNovember 06, 2018

Tag: FDA , GSK , Potiga

PharmaSources Customer Service